Results 11 to 20 of about 61,179 (292)
Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. [PDF]
PLoS ONE, 2015 Allopurinol, an inhibitor of xanthine oxidase, has been used in clinical trials of patients with cardiovascular and chronic kidney disease. These are two pathologies with extensive links to hypoxia and activation of the transcription factor hypoxia ...
Yu Sun +3 more
doaj +14 more sources
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
New England Journal of Medicine, 2018 William B White +2 more
exaly +2 more sources
The anti-inflammatory effect of allopurinol and diclofenac in chicks’ model [PDF]
Iraqi Journal of Veterinary Sciences, 2023 No studies have been conducted on the anti-inflammatory effect of allopurinol; eight-day old chicks are used. The aim of this paper was to study the anti-inflammatory action of allopurinol on a chemical pain model, both when administered alone or in ...
Maab A. Fadel, Khayrea A. Mustafa
doaj +1 more source
Serendipitous Symptom Control: Allopurinol for Spasticity in a Case of SPG4-Linked Hereditary Spastic Paraplegia-A Case Report. [PDF]
Clin Case RepGraphical representation of spasticity and medication changes. (A) Temporal course of lower limb spasticity measured by MAS scores. Following initiation of allopurinol 300 mg daily at baseline (red dashed line), there was a rapid and sustained improvement in spasticity from severe (MAS = 4) to mild (MAS = 1.8) over 12 months of follow‐up, represented ...
Elmezayen ZW +3 more
europepmc +2 more sources
Optimizing adherence to allopurinol for gout: patients' perspectives
British Journal of Clinical Pharmacology, 2023 Poor adherence to allopurinol among people with gout contributes to suboptimal gout management. This study sought to understand the facilitators and barriers to allopurinol adherence across the three stages of medication adherence, and patient ...
J. Spragg +6 more
semanticscholar +1 more source
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.
NEJM Evidence, 2022 BACKGROUND The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues.
J. O'dell +16 more
semanticscholar +1 more source
Inflammation, 2022 SARS-CoV-2 by the direct cytopathic effect or indirectly through the propagation of pro-inflammatory cytokines could cause endothelial dysfunction (ED) and oxidative stress (OS).
H. Al-kuraishy +6 more
semanticscholar +1 more source
Annals of Internal Medicine, 2022 BACKGROUND Two recent randomized clinical trials of escalating doses of allopurinol for the progression of chronic kidney disease (CKD) reported no benefits but potentially increased risk for death.
Jie Wei +11 more
semanticscholar +1 more source
Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats
Journal of Pharmaceutical Health Care and Sciences, 2022 Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and oxypurinol are potent XO inhibitors that reduce the plasma uric acid levels.
Yoshitaka Tayama +5 more
doaj +1 more source
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
European Heart Journal, 2021 Aims With the high prevalence of gout and associated cardiovascular (CV) diseases, information on the comparative CV safety of individual urate-lowering drugs becomes increasingly important. However, few studies examined the CV risk of uricosuric agents.
E. Kang +4 more
semanticscholar +1 more source